ProMIS Neurosciences researchers have discovered new antibody candidates that selectively bind to the neurotoxic form of the tau protein — one of the hallmarks of Alzheimer’s disease.
These new antibodies join the company’s PMN310, a humanized antibody that attacks only toxic forms of the amyloid beta protein linked to Alzheimer’s.
Read the full article from Alzheimer’s News Today